as 11-21-2024 10:36am EST
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.
To train our stocks LPCN ML model, we use historical data with over 25 parameters, including volume indicators, volatility indicators, momentum indicators, trend indicators, and other metrics.
We update our ML model either weekly or biweekly, depending on the market capitalization of the stocks, using TensorFlow, typically over the weekend.
Unfortunately, our current data provider offers limited historical data, which impacts the accuracy of our ML model. However, as we continue to gather more data over time and add more indicators, we expect the accuracy of our model to improve.
We would greatly appreciate your contribution. Please send an email to [email protected]
Yes, we offer it for strategy purposes only, with intervals: 1 minute, 2 minutes, 5 minutes, 15 minutes, and 30 minutes etc.
Our ML model is primarily designed for educational purposes and is not intended to provide financial advice. We strongly recommend consulting with a financial advisor before making any buying or selling decisions.
Our LPCN ML model is developed exclusively for educational purposes. Any information presented on this page regarding the '"LPCN Forecast & Prediction for November 21, 2024 Lipocine Inc." should not be considered as financial advice or as a recommendation to buy or sell stocks. It is provided strictly for educational purposes. Investing in stocks involves significant risks, and decisions should be made only after careful consideration and consultation with a qualified financial advisor.